Leading Professional Society for Computational Biology and Bioinformatics
Connecting, Training, Empowering, Worldwide

Upcoming Conferences

A Global Community

  • ISCB Student Council

    dedicated to facilitating development for students and young researchers

  • Affiliated Groups

    The ISCB Affiliates program is designed to forge links between ISCB and regional non-profit membership groups, centers, institutes and networks that involve researchers from various institutions and/or organizations within a defined geographic region involved in the advancement of bioinformatics. Such groups have regular meetings either in person or online, and an organizing body in the form of a board of directors or steering committee. If you are interested in affiliating your regional membership group, center, institute or network with ISCB, please review these guidelines (.pdf) and submit your application using the online ISCB Affiliated Group Application form. Your exploratory questions to ISCB about the appropriateness of a potential future affiliation are also welcome by Diane E. Kovats, ISCB Executive Director (This email address is being protected from spambots. You need JavaScript enabled to view it.).

  • Communities of Special Interest

    topically-focused collaborative communities


  • ISCBconnect

    open dialogue and collaboration to solve problems and identify opportunities

  • ISCB Member Directory

    connect with ISCB worldwide

  • ISCB Innovation Forum

    a unique opportunity for industry

Professional Development, Training and Education

ISCBintel and Achievements


Links within this page:
Plane | Train | Bus | Car

Whether you live across the Hudson or across the Atlantic, getting to NYC is easy. If you’re coming from outside the United States, check this page for visa information.

See below for the best ways to reach the five boroughs from anywhere in the world.

By plane If you’re coming from far away, you’ll probably want to fly into one of the New York City area’s major airports. There are a number of hotels conveniently located near the City’s airports.

By Plane

Below, you'll find a list of NYC-area airports, along with the best ways to get from those airports to Manhattan. There are more than a hundred air carriers traveling to NYC from all over the country and the world, including American Airlines, Delta, JetBlue and United.

Air travelers to New York City may arrive at John F. Kennedy International Airport (JFK) or LaGuardia Airport (LGA), both in Queens, or Newark Liberty International Airport (EWR) in neighboring New Jersey. LaGuardia primarily serves domestic destinations, and also offers flights to select Canadian and Caribbean destinations. Kennedy and Newark both serve domestic and international destinations. Visitors can reach Manhattan from all three airports by using taxis, buses, subways and/or commuter trains. Other metropolitan-area airports include Stewart International Airport (SWF), Westchester County Airport (HPN) and MacArthur Airport (ISP). For those interested, there are a number of hotels conveniently located near the City's airports.

John F. Kennedy International Airport (JFK)
Jamaica, Queens, NY 11430

New York's largest airport serves more than 80 airlines, most of which are international. It is approximately 15 miles from Midtown Manhattan. Here's how to get to Midtown Manhattan from JFK:

  • Taxi: $52.50 flat fare (non-metered), plus bridge and tunnel tolls and gratuity; 30 to 60 minutes to Midtown Manhattan, depending on traffic and road conditions. For more information, call 212-NYC-TAXI or visit the Taxi and Limousine Commission website.
  • AirTrain JFK: $5 (children under 5 are free); AirTrain links the airport to the subway and Long Island Rail Road. AirTrain also offers free service between points in the airport.
  • Subway: one ride (in addition to AirTrain fare) from the A subway stop at the Howard Beach/JFK Airport station or the E, J or Z subway stop at the Sutphin Blvd./Archer Ave./JFK Airport station; 60 to 75 minutes to Midtown Manhattan.
  • Long Island Rail Road (LIRR): $7.25–$10 (children under 5 are free), depending on time of day (in addition to AirTrain fare) for the trip between LIRR's Jamaica Station and Penn Station; on Saturday and Sunday, the fare is $4.25. The trip is 20 minutes to Midtown Manhattan (not including AirTrain ride).
  • City bus: For details, visit tripplanner.mta.info.
  • Shuttle bus: NYC Airporter, Go Airlink NYC and SuperShuttle.
  • Private car service: See this list of providers.
  • Car rental: Companies at JFK include Avis, Budget, Dollar, Enterprise, Hertz and National.

LaGuardia Airport (LGA)
Jackson Heights, Queens, NY 11371

This is New York's second-largest airport, with nearly 20 airlines serving mostly domestic destinations, as well as Canada and the Caribbean, from four passenger terminals. LaGuardia is on the northern shore of Queens, directly across the East River (about 8 miles from Midtown Manhattan). Here's how to get to Midtown Manhattan from LaGuardia:

Newark Liberty International Airport (EWR)
Newark, NJ 07114

Newark Airport, with more than 30 airlines (many of which are international), is across the Hudson River from New York City—16 miles from Midtown Manhattan. Here's how to get to Midtown Manhattan from Newark Liberty:

  • Taxi: Traveling to Manhattan, metered fare; approximately $50 to $75, plus bridge and tunnel tolls and gratuity; 45 to 60 minutes to Midtown Manhattan. During weekday rush hours (6–9am and 4–7pm) and on weekends (Saturday–Sunday, noon–8pm), there is a $5 surcharge for travel to anywhere in New York State except Staten Island. When traveling to the airport from Midtown Manhattan, service is via New York City’s regulated yellow taxis. Metered fares range $69–$75, plus a $17.50 surcharge in addition to tolls and gratuity.
  • AirTrain Newark: Costs vary by destination. AirTrain links to the airport via NJ Transit and Amtrak's Newark (or EWR) train station; 45 to 90 minutes to Midtown Manhattan, requiring a transfer from the AirTrain line to the NJ Transit line (be sure to keep your ticket after using it to exit the AirTrain station, as it is also used for the NJ Transit fare) or Amtrak. AirTrain also offers free service between points in within the airport complex, including hotels and parking. Look for signs marked “Monorail/AirTrain Link” (do not follow signs for Ground Transportation).
  • Shuttle bus: NYC Airporter, Go Airlink NYC, Olympia Airport Express and SuperShuttle.
  • Private car and limousine service: Dial 7, Carmel and Uber.
  • Car rental: Companies at Newark include Avis, Budget, Dollar, Enterprise, Hertz and National.

Stewart International Airport (SWF)
New Windsor, NY 12553

Stewart International Airport is 60 miles north of New York City. Here's how to get to Midtown Manhattan from Stewart:

  • Bus/train: Leprechaun Lines runs a $1 shuttle bus on their Newburgh-Beacon-Stewart commuter line, which connects to the Beacon train station. There, use Metro-North Railroad for direct service to Grand Central Terminal ($16 off-peak, $21.25 peak); 70 to 90 minutes to Midtown Manhattan.

- top -

By Train

New York City has two main rail stations in Midtown: Grand Central Terminal (on the east side) and Penn Station (on the west side). Each is also served by numerous bus and subway lines. Grand Central is served by Metro-North Railroad, which goes to NYC suburbs in New York and Connecticut. Penn Station is served by the following: Long Island Rail Road, a commuter railroad serving Long Island; Amtrak, the US national passenger railroad, serving many points throughout the country; and NJ Transit, a commuter line serving points in New Jersey.

  • Rail Terminals
    • Grand Central Terminal
      Park Avenue and East 42nd Street (between Lexington and Vanderbilt Avenues)
      Grand Central is the main terminal for Metro-North Railroad services. Subway lines here include the 4, 5, 6, 7 and S (shuttle between Grand Central and Times Square). For MTA bus details, visit tripplanner.mta.info.

      Aside from being a transit hub, Grand Central is also a landmark and an attraction unto itself. The Main Concourse boasts an immense 88,000 square feet of space, and on sunny days is bathed in light from its giant arching windows. Grand Central's 12-story ceiling is painted with stars and gilded zodiac constellations. Not only might Grand Central be the globe's most beautiful train station, the 49-acre terminal is also one of the world's largest. There are numerous shops of all varieties here, including an Apple Store, MAC Cosmetics and Tumi. The dining concourse on the lower level features a wide selection of eateries, and in Grand Central Market, fresh and prepared foods—ranging from baked goods to gourmet teas—are available.
    • Penn Station
      Seventh to Eighth Avenues, between West 31st and West 33rd Streets
      Penn Station is the main terminal for Long Island Rail Road, and a terminal for Amtrak and NJ Transit. Subway lines here include the 1, 2, 3, A, C and E. For MTA bus details, visit tripplanner.mta.info.

      Penn Station's main concourse features information booths, restaurants, waiting rooms and public restrooms to accommodate the thousands of passengers who pass through the terminal each day. In 2016, the new West End Concourse will open providing additional access to the station from 8th avenue. Car rental offices are nearby.
  • Rail Services
    • Amtrak
      800-872-7245, 212-630-6400
      Amtrak is the national passenger railroad of the United States. New York City's Penn Station is their busiest station in the nation, serving hundreds of thousands of passengers each year. The company offers numerous packages and deals, including special passes allowing international visitors to make multiple stops throughout the country.
    • Long Island Rail Road (LIRR)
      This commuter railroad operates out of Penn Station and serves 124 stations in Nassau County, Suffolk County, Queens, Brooklyn and Manhattan, transporting some 81 million customers each year. Destinations include the Belmont Park racetrack, Citi Field, Jones Beach, the Hamptons and Montauk.
    • Metro-North Railroad
      212-532-4900, 877-690-5114
      The second-largest commuter train line in the United States, Metro-North operates out of Grand Central Terminal. The historic roots of the operation go back to 1832, when the enterprise was known as the New York & Harlem Railroad, a horsecar line in Lower Manhattan. Today, with 775 miles of track, Metro-North goes to 121 stations (in seven New York State counties—Dutchess, Putnam, Westchester, Rockland, Orange, Bronx and New York (Manhattan)—and Connecticut's New Haven and Fairfield counties).
    • NJ Transit
      973-275-5555, TTY 800-772-2287
      This rail system features 12 lines in three divisions (Hoboken, Newark and the Atlantic City Rail Line) with frequent service throughout New Jersey (Atlantic City and the Jersey Shore are popular stops) and New York (Rockland and Orange counties)—and, of course, into and out of New York City via Penn Station. For schedules and fares, visit the NJ Transit website.
    • PATH (Port Authority Trans Hudson)
      The PATH provides rapid transit between several stops in New York City, along with locations in Newark, Harrison, Jersey City and Hoboken in New Jersey. Air travelers can connect to the PATH from Newark Liberty International Airport. The service operates from the Penn Station in Newark (not the same as Manhattan's Penn Station) to Lower and Midtown Manhattan. The PATH's 33rd Street station (on Sixth Avenue, in Herald Square) in Manhattan is one avenue from Amtrak, Long Island Rail Road and NJ Transit trains at Penn Station.

- top -

By Bus

There are a number of affordable, convenient bus lines that travel to New York City from around the United States and parts of Canada. These include BoltBus, Megabus and Greyhound.

- top -

By Car

Use Google Maps for driving directions to New York City. Also, make sure you know where to park: you may want to use an app like SpotHero to find and compare parking spots and locations.

- top -

RSG and DREAM General Questions

Bel Hanson, Conference Manager
Tel: 1-571-293-0286

Source: NYC The Official Guide

- top -


Ross Cagan, PhD

Ross Cagan, PhD
Senior Associate Dean for the Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, USA

Aravinda Chakravarti, PhD
Professor of Medicine, Pediatrics, Molecular Biology & Genetics, and Biostatistics and Neuroscience, New York University School of Medicine, USA
Aravinda-Chakravarti, PhD
Itai Yanai, PhD Itai Yanai, PhD
Director, Institute for Computational Medicine
Professor, Biochemistry and Molecular Pharmacology
New York University, School of Medicine, USA

Peter Kharchenko, PhD
Assistant Professor of Biomedical Informatics, Harvard University, USA

Peter Kharchenko, PhD
Daphne Koller, PhD

Daphne Koller, PhD
Stanford University, USA

Xiaole Shirley Liu, PhD
Professor of Statistics, Biostatistics, and Computational Biology, Harvard University, Dana-Farber Cancer Institute, USA

Xiaole Shirley Liu, PhD
Miriam Merad, PhD

Miriam Merad, PhD
Icahn School of Medicine at Mount Sinai, USA

Ana Pombo, PhD
Berlin Institute for Medical Systems Biology, at the Max Delbrueck Center, Germany

Ana Pombo, PhD
Bing Ren, PhD

Bing Ren, PhD
Professor of Cellular and Molecular Medicine, UC San Diego, USA

Adam Siepel, PhD
Professor, Watson School of Biological Sciences
Chair, Simons Center for Quantitative Biology
Cold Spring Harbor Laboratory, USA
Adam Siepel, PhD

- top -

Keynote Bios

Ross Cagan, PhDRoss Cagan, PhD
Senior Associate Dean for the Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, USA

Ross L. Cagan, PhD, is Professor of the Department of Developmental and Regenerative Biology and Director of the Center for Personalized Cancer Therapeutics. He is also Senior Editor of Disease Models and Mechanisms and co-founder of Medros Inc.

Dr. Cagan's laboratory focuses on the use of Drosophila to address disease mechanisms and therapeutics, primarily for cancer. Their work helped validate vandetanib as a therapeutic for Medullary Thyroid Carcinoma, combined Drosophila genetics and medicinal chemistry to develop a new generation of lead compounds that emphasize "balanced polypharmacology", and identified novel mechanisms that direct transformed cells into the first steps towards metastasis.

Combining these basic research approaches, Dr. Cagan has established the Center for Personalized Cancer Therapeutics, in which new tools including 'personalized Drosophila avatars' are developed and used to screen for personalized drug cocktails. Working with co-directors Marshall Posner and Eric Schadt, the CPCT is designed to treat patients with drug combinations that best address the tumor's complexities.

A key challenge in many diseases including cancer and neurodegenerative diseases is their complexity. Genomic changes and interactions within a whole body setting can lead to emergent properties that present significant therapeutic challenges. In our DREAM challenge, the community has worked to develop new approaches to developing therapeutic candidates that embrace complexity.

- top -

Aravinda-Chakravarti, PhDAravinda Chakravarti, PhD
Professor of Medicine, Pediatrics, Molecular Biology & Genetics, and Biostatistics and Neuroscience, New York University School of Medicine, USA

Dr. Aravinda Chakravarti is Professor of Medicine, Pediatrics, Molecular Biology & Genetics, and Biostatistics and Neuroscience at the New York University School of Medicine, and inaugural Director of its Center for Human Genetics and Genomics. He was the 2008 President of the American Society of Human Genetics, and has been elected to the U.S. National Academy of Science, the U.S. National Academy of Medicine, the Indian National Academy of Sciences, and the Indian Academy of Sciences. He has been a key participant and architect of the Human Genome, HapMap, and 1000 Genomes project. His research is aimed at genome-scale analysis of humans and computational analysis of gene variation and function to understand the molecular genetic basis of complex human disease. For his contributions to human genetics and genomics he was awarded the William Allan Award in 2013 by the American Society of Human Genetics.  Aravinda Chakravarti received his doctoral degree in human genetics in 1979 and started his faculty career at the University of Pittsburgh (1980–1993), was the James H. Jewell Professor of Genetics at Case Western Reserve University (1994-2000), and the inaugural Director and Henry J. Knott Professor of the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins (2000-2007). He is one of the founding Editors-in-Chief of Genome Research and Annual Reviews of Genomics & Human Genetics, and serves on the boards of numerous private Institutes and charities, international journals, academic societies, the NIH and biotechnology companies.

- top -

Peter Kharchenko, PhDPeter Kharchenko, PhD
Assistant Professor of Biomedical Informatics, Harvard University, USA

Peter Kharchenko received a PhD in biophysics at Harvard University, studying gene regulation and metabolic networks under the advisement of George Church. He then completed a four-year postdoctoral fellowship in computational biology and genomics in the laboratory of Peter Park. His lab specializes in development of statistical and computational methods for analysis of genomic data, including single-cell genomics,  as well as application of these approaches to studies of normal and cancer tissue organization.

- top -

Daphne Koller, PhD

Daphne Koller, PhD
Stanford University, USA

Daphne Koller (PhD) is the CEO and Founder of insitro, a startup company that aims to rethink drug development using machine learning. She also co-founded and led Coursera, the largest platform for massive open online courses (MOOCs). Daphne was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years. She has also been the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 200-refereed publications appearing in venues such as Science, Cell, and Nature Genetics. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012 and Newsweek’s 10 most important people in 2010. She has been honored with multiple awards and fellowships during her career including the Sloan Foundation Faculty Fellowship in 1996, the ONR Young Investigator Award in 1998, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, the IJCAI Computers and Thought Award in 2001, the MacArthur Foundation Fellowship in 2004, and the ACM Prize in Computing in 2008. Daphne was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017. Her teaching was recognized via the Stanford Medal for Excellence in Fostering Undergraduate Research, and as a Bass University Fellow in Undergraduate Education.

- top -

Xiaole Shirley Liu, PhDXiaole Shirley Liu
Professor of Statistics, Biostatistics, and Computational Biology, Harvard University, Dana-Farber Cancer Institute, USA

Xiaole Shirley Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. She is now Professor of Statistics, Biostatistics and Computational Biology at Harvard University, Director of the Center of Functional Cancer Epigenetics at Dana-Farber Cancer Institute, associate member of the Broad Institute, and Visiting Professor of Bioinformatics at Tongji Univ. She is a member of the ENCODE consortium and the lead investigator for the Cancer Immune Data Common from National Cancer Institute. Her research focuses on algorithm development and integrative modeling of high throughput genomic data to understand the specificity and function of regulator genes in tumor development, progression, drug response and resistance. She is especially interested in genomics and bioinformatics approaches in cancer epigenetics, cancer immunology, and CRISPR screens for translational cancer research. Her lab developed widely used analysis algorithms for transcription factor motif discovery, ChIP-chip/seq, CRISPR screen, and tumor immune repertoire data analysis. Her computational modeling helped the understanding of ER, AR, FoxA1, XBP1, JARID1B, PBAF regulation as well as BET bromodomain inhibitor, gamma secretase inhibitor, CDK4/6 inhibitor, and immune checkpoint inhibitor function in different cancers in different cancers. Dr. Liu has an H-index of 79 according to Google Scholar statistics and has published over 50 papers in Nature, Science or Cell series journals. She is the recipient of the Sloan Research Fellowship, the Richard E. Weitzman Outstanding Early Career Investigator Award from the Endocrine Society, the Claire W. and Richard P. Morse Research Award, the Breast Cancer Research Foundation Investigator, the Yangtze River Scholar and 1000 Talent Scholar in China. She has successfully mentored sixteen trainees to start tenure track faculty positions.

Hidden immunology signals in tumor RNA-seq
Tumor RNA-seq data contain rich information about the tumor immune microenvironment. I will discuss two computational algorithms TIDE and TRUST developed in our lab.

Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we developed TIDE, a computational method to model two primary mechanisms of tumor immune evasion: the induction of T cell dysfunction in tumors with high infiltration of cytotoxic T lymphocytes (CTL) and the prevention of T cell infiltration in tumors with low CTL level. We identified signatures of T cell dysfunction from large tumor cohorts by testing how the expression of each gene in tumors interacts with the CTL infiltration level to influence patient survival. We also modeled factors that exclude T cell infiltration into tumors using expression signatures from immunosup- pressive cells. Using this framework and pre-treatment RNA-Seq or NanoString tumor expression profiles, TIDE predicted the outcome of melanoma patients treated with first-line anti-PD1 or anti-CTLA4 more accurately than other biomarkers such as PD-L1 level and mutation load. TIDE also revealed new candidate ICB resistance regulators, such as SERPINB9, demonstrating utility for immunotherapy research.

Tumor-infiltrating B cell is an important component in the microenvironment with unclear anti-tumor impacts. We enhanced our previous computational algorithm TRUST to extract the B cell immunoglobulin (Ig) hypervariable regions from bulk tumor RNA-seq data. TRUST assembled over 30 million complementarity-determining region 3 (CDR3s) of the B cell heavy chain (IgH) from The Cancer Genome Atlas (TCGA). Widespread B cell clonal expansions and Ig subclass switch events were observed in diverse human cancers. Prevalent somatic copy number alterations (SCNA) in MICA/B genes related to antibody-dependent cell mediated cytotoxicity (ADCC) were identified in tumors with elevated B cell activity. IgG3-1 subclass switch interacts with the B cell receptor affinity maturation and defects in the ADCC pathway. The comprehensive pan-cancer analyses of tumor-infiltrating B cell receptor repertoires revealed novel tumor immune evasion mechanism through genetic alterations. The IgH sequences identified in this work are potentially useful resources for future development of immunotherapies.

- top -

Miriam Merad, PhDMiriam Merad, PhD
Icahn School of Medicine at Mount Sinai, USA

Miriam Merad, M.D.; Ph.D. is the Mount Sinai Chair professor in Cancer Immunology and the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York.
Dr. Merad obtained her MD at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her PhD in immunology in collaboration between Stanford University and University of Paris VII. She was recruited to Mount Sinai in 2004 and was promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010 and in 2014, she obtained an Endowed Chair Professor in Cancer Immunology.

Dr. Merad’s laboratory studies the contribution of macrophages and dendritic cells to Cancer and Inflammatory disease in mice and Human. Dr. Merad’s pioneering work mapping the regulatory network of dendritic cells (DCs) resulted in identification of a lineage of DC, the CD103+ DC, that is now considered a key target to improve antiviral and antitumor immunity.   Another of her key discoveries is that, contrary to the previously-held beliefs that monocytes are precursors of macrophages, she found that tissue-resident macrophages in fact arise from embryonic precursors that take residence in tissues prior to birth and are maintained independently of adult hematopoiesis. These insights are now being used to develop novel macrophage and dendritic cell-specific targets for the treatment of Cancer and Inflammatory diseases.  Dr. Merad has authored more than 160 primary papers and reviews in high profile journals. Dr. Merad receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and their contribution to human disease, and belongs to several NIH consortia. She is an elected member of the American Society of Clinical Investigation, and lectures around the world on her work.

Single Cell Approaches To Guide Novel Diagnostics And Precise Therapies
Immunological diseases arise from a complex interplay of genetic and environmental factors favoring tissue-damaging responses. Although many genetic susceptibility loci have been linked to these diseases, genetic information have failed to predict disease course or disease response to treatment.
Here I will discuss how single cell approaches are helping dissect disease heterogeneity, identify prominent pathophysiological processes and novel therapeutic avenues. I will also discuss novel single cell approaches that combine proteomics and RNAseq at the single cell level and how these approaches are strongly enhancing genomic data and our understanding of disease pathophysiology.

- top -

Ana Pombo, PhDAna Pombo, PhD
Berlin Institute for Medical Systems Biology, at the Max Delbrueck Center, Germany

Ana Pombo investigates how the 3D folding of chromosomes influences gene expression in mammalian development and disease, and epigenetic mechanisms that prime genes for future activation. She received her DPhil from University of Oxford (1998, UK) where she identified transcription factories in mammalian nuclei. She was awarded a Royal Society Dorothy Hodgkin Fellowship (UK; 1998-2002), and started leading her research group in 2000 at the MRC London Institute for Medical Sciences, Imperial College London (UK). Her laboratory moved to the Berlin Institute for Medical Systems Biology, at the Max Delbrueck Center (Berlin, Germany) in 2013, and she was appointed Professor (W3) at Humboldt University of Berlin. Her lab has developed Genome Architecture Mapping (GAM), an exquisite technology to map the 3D structure of chromosomes genome-wide. GAM is uniquely powerful to quantify the higher-order complexity of 3D genome and the study of rare cell types directly from tissue, avoiding dissociation, including from precious human biopsies. These developments open a huge field of potential applications to identify the
genes affected by disease-associated genetic variants present in non-coding parts of the genome, through long-range chromatin contacts.

- top -

Bing Ren, PhDBing Ren, PhD
Professor of Cellular and Molecular Medicine, UC San Diego, USA

Dr. Ren is Member of the Ludwig Cancer Research (LCR), Professor of Cellular and Molecular Medicine at the University of California, San Diego (UCSD), and Director of the UCSD Center for Epigenomics. Dr. Ren obtained his Ph.D. from Harvard University in 1998, and subsequently conducted postdoc research at the Whitehead Institute. He joined the faculty at LCR and UCSD in 2001, and was promoted to Associate Professor in 2007 and to Full Professor in 2009.  Dr. Ren is studying how gene expression is regulated in mammalian cells, and how its dysregulation leads to cancer and other human disease. His lab has developed transformative tools and concepts for global analysis of transcriptional control elements and chromatin organization.  He is a recipient of the Chen Award for Distinguished Academic Achievement in Human Genetic and Genomic Research, and an elected fellow of the American Association for the Advancement of Science.

Functional Organization of the Human Genome
The 3-dimentional architecture of chromosomes in eukaryotic cells enables long-range communication between enhancers and promoters, and contributes to spatiotemporal gene expression programs in multicellular species. Detailed knowledge of how chromatin architecture dynamically reorganizes during development and in different cell types is critical for studying the gene regulatory programs controlling cell fate specification and elucidating the molecular basis of human diseases. We have delineated the dynamic chromatin architecture at high resolution during key developmental stages of human cardiomyocyte differentiation from embryonic stem cells. We observed dramatic changes in chromatin compartments, topological domains and enhancer/promoter interactions, which was correlated with dynamic gene expression patterns. The chromatin loop interactions help us to predict target genes of non-coding genetic variants associated with cardiac-related traits/diseases. We also generate maps of long-range chromatin interactions centered on human promoters in a large panel of human cell/tissue types. We use this information to infer the target genes of candidate regulatory elements, and suggest potential regulatory function for non-coding sequence variants associated with a large number of physiological traits and diseases. Integrative analysis of these promoter-centered interactome maps reveals widespread enhancer-like promoters involved in gene regulation and common molecular pathways underlying distinct groups of human traits and diseases.

- top -

Adam Siepel, PhDAdam Siepel, PhD
Professor, Watson School of Biological Sciences
Chair, Simons Center for Quantitative Biology
Cold Spring Harbor Laboratory, USA

Adam Siepel is a Professor in the Watson School of Biological Sciences and Chair of the Simons Center for Quantitative Biology at Cold Spring Harbor Laboratory, with adjunct appointments at Cornell University and Stony Brook University. Originally trained as a computer scientist, Siepel has done influential work in molecular evolution, human population genetics, and transcriptional regulation. He was a member of the faculty of the department of Biological Statistics and Computational Biology at Cornell University from 2006-2014 and has been at Cold Spring Harbor Laboratory since 2014.  Siepel is a winner of a Guggenheim Fellowship, a Microsoft Research Faculty Fellowship, a Packard Fellowship, a National Science Foundation CAREER Award, and a Sloan Research Fellowship.

An evolutionary framework for measuring epigenomic information and estimating cell-type specific fitness consequences
How much information do epigenomic data sets provide about human genomic function? We have addressed this question by considering nine epigenomic features across 115 cell types from the Roadmap Epigenomics project. We measure information about function as a reduction in entropy under a probabilistic evolutionary model fitted to human and nonhuman primate genomes. We find that several epigenomic features yield more information in combination than they do individually, and that the entropy in human genetic variation predominantly reflects a balance between mutation and neutral drift. Our cell-type specific FitCons scores reveal relationships among cell types and suggest that ~8% of nucleotide sites are constrained by natural selection.

- top -

Itai Yanai, PhDItai Yanai, PhD
Director, Institute for Computational Medicine
Professor, Biochemistry and Molecular Pharmacology
New York University, School of Medicine, USA

Dr. Itai Yanai joined the faculty at New York University’s School of Medicine in May 2016 as a professor in the Department of Biochemistry and Molecular Pharmacology. He serves as the inaugural director of the Institute for Computational Medicine (ICM), whose goal is to harness computational approaches for fundamental and medically-relevant discoveries. Through the development of novel tools, the nurturing of young investigators, and translational applications, ICM aims to create a culture that promotes scientific advancements.

Dr. Yanai’s research focuses on the interface of gene expression, development, and evolution. Using his training as an experimental embryologist, a molecular biologist, and a computational biologist, his interest is exploring how developmental pathways evolve at the molecular level. Members of his lab carry out intricate embryological experiments at the level of individual cells and apply computational approaches to explore the resulting data. As a model system, they use the best understood animal, the nematode C. elegans. His lab developed the popular CEL-Seq method for single-cell RNA-Seq and they have used it to study stages, germ-layers, and body-plans in animal embryos. More recently, his lab is applying single-cell RNA-Seq to the study of tumorigenesis and bacterial infection.

Dr. Yanai received his undergraduate degrees in Computer Engineering and the Philosophy of Science and his PhD in Bioinformatics from Boston University in 1997 and 2002, respectively. He completed a postdoctoral fellowship in Molecular Genetics in 2004 at the Weizmann Institute of Science in Israel and a postdoctoral fellowship in Developmental Genetics at Harvard University in 2008. At the Technion–Israel Institute of Technology, he served as an Assistant Professor in the Department of Biology from 2008-2013 and Associate Professor from 2014-2016. He was a Radcliffe Fellow, Radcliffe Institute for Advanced Study, Harvard University, and a visiting professor, Broad Institute of Harvard and MIT, from 2014-2015.

In addition to his research goals, Dr. Yanai firmly believes that the communication of knowledge is a major component of science and is involved in mentoring students, giving presentations, participating in outreach programs and in the dissemination of science to a popular audience. Towards this end, Dr. Yanai has also co-authored a popular science book, entitled “The Society of Genes”, along with Dr. Martin Lercher from Heinrich-Heine University in Düsseldorf. 

Single-cell and spatial gene expression analysis of tumorigenesis

- top -

Call for Editors – ISCB Community Journal


ISCB is seeking scholars interested in serving as volunteer editors for the ISCB Community Journal. If you are interested, please submit your nomination using our online system.  If you have a colleague who may enjoy serving as a volunteer editor for ISCB, please feel free to forward this information.


The primary responsibility of an editor will be to oversee the content on the ISCB Community Journal homepage. Editors will work with the conferences and have the final decision on the selection of  conference editors and editorial board proposed by the conferences. Editors will supervise the conference referee process and ensure the quality standards of referee reports, editorial decision and published papers. Editors will help to promote the journal and to increase the number of conferences publishing in the journal.   The ISCB Community Journal editors will work closely with F1000Research to keep improving the journal and make sure it is meeting the aims and objectives of the ISCB.  Editors are appointed by the ISCB Board of Directors and will serve a three-year term* with the option to be renewed for one additional term.


Applicants must be a member of ISCB and have significant publishing and reviewing experience, and experience reviewing and working with conference paper and abstract submissions.  Due to the high volume of applications, only accepted applicants will be contacted via email.


Be prepared to submit the following information:

Your name

Email address


City, State, Country


Name of your institution

Department or Division

Website of institution

Your title or position


Your highest degree

Years of editing or peer review experience

Which journals do you currently serve (List of Journals and specific role)?

Which conferences have you supported the review of submissions or program decisions?


Statement of interest that further support your nomination (cannot exceed 50 words).


Up to one page CV


*Terms will be staggered to ensure continuity for the journal.  First year editors are not guaranteed a full three-year term.

2014 ISCB Fellows Keynote

Russ B. Altman, MD, PhD

Professor of Bioengineering, Genetics, and Medicine and Computer Science

Director, Biomedical Informatics Training Program
Stanford University, United States

website: http://helix-web.stanford.edu/people/altman/

Presentation Title: Informatics for understanding drug response at all scales

Presentation Time: Tuesday July 15, 4:40 pm - 5:40 pm

Introduction by: Reinhard Schneider, ISCB Treasurer



An understanding of drug action at multiple levels is required for optimal use of existing drugs, as well as for identifying new opportunities for therapeutics.  Unlike many experimental programs, informatics programs for drug action can integrate data of length scales across length scales spanning more than 6 orders of magnitude: from molecular to global populations.  In this talk, I will discuss how we have developed methods at the molecular, cellular, individual organism and population to understand drug response phenotypes, and the underlying molecular mechanism of these responses.  This information can be used for understanding personalized medicine (pharmacogenomics), drug interactions, drug repurposing and druggability of orphan genes.


Russ Biagio Altman is a professor of bioengineering, genetics, & medicine (and of computer science, by courtesy) and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing and informatics technologies to basic biological problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels. His lab studies how human genetic variation impacts drug response (e.g. http://www.pharmgkb.org/). Other work focuses on the analysis of biological molecules to understand the action, interaction and adverse events of drugs (http://features.stanford.edu/). He leads one of seven NIH-supported National Centers for Biomedical Computation, focusing on physics-based simulation of biological structures (http://simbios.stanford.edu/). Dr. Altman holds an A.B. from Harvard College, and M.D. from Stanford Medical School, and a Ph.D. in Medical Information Sciences from Stanford. He received the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians, the American College of Medical Informatics, and the American Institute of Medical and Biological Engineering. He is a member of the Institute of Medicine of the National Academies. He is a past-president, founding board member, and a Fellow of the International Society for Computational Biology, and the President-Elect of the American Society for Clinical Pharmacology & Therapeutics. He currently chairs the Science Board advising the FDA Commissioner. He is an organizer of the annual Pacific Symposium on Biocomputing (http://psb.stanford.edu/), and a founder of Personalis, Inc. He won the Stanford Medical School graduate teaching award in 2000.

Welcome to the seventh annual Rocky Mountain Bioinformatics Conference, a meeting of the International Society for Computational Biology (ISCB). The organizers hope that you enjoy the program, and find the conference a productive opportunity to meet researchers, students and industrial users of bioinformatics technology. We think we have the best program yet, offering a remarkable cross-section of bioinformatics research.

The Rocky series began seven years ago as a regional conference, and has grown into an international program with a spotlight on regional development in the computational biosciences. The presenters of the Rocky conference are scientists representing a broad spectrum of universities, industrial enterprises, government laboratories, and medical libraries from around the world. The meeting is a chance to get to know your colleagues near and far, seek collaborative opportunities, and find synergies that can drive our field forward.

For 2009 we will continue with the changes made in 2008 with extending the meeting to three full days, keeping the short talks to 10 minutes, and keeping with a larger poster session, allowing everyone who wants to present to do so. And we've retained the lunchtime ski breaks so that those of you who want to ski, including beginners, will have a chance to do so among friends and colleagues.

We hope you enjoy the science, the company, and the spectacular scenery of the Rocky Mountains. Welcome!

Larry Hunter
Rocky '09 Conference Chair

Rocky '08 Comments

  • 100% of the delegates found the conference met or exceeded their expectations

  • 100% of the delegates found the conference was fair/good value

  • 90% of the delegates said they would attend again

  • “This was my first time attending the meeting. I was very dubious about the 10 minute talks. I was completely wrong. The talks were great. The conference was very well organized.”

  • “As a primarily wet lab biologists. I did not have the necessary math/cs background, but I learned about many ideas”

  • “As always, wonderful meeting in a great location. It is an excellent mix of different areas of science and a great way to meet new people. See you next year too.”

  • “I have attended Rocky several times and I always learn something valuable.”
  • “This has been a great conference. I look forward to attending next year.”


Submit Comments to NIH on Clinical Trials Registry Database Implementation through September 2008

NIH has issued a notice announcing its intent to implement the expanded clinical trials registry and basic results databases required by the Food and Drug Administration Amendments Act of 2007. Public comments received on these materials will inform development of an operational basic results database and preparation of a Notice of Proposed Rule Making regarding development of an expanded registry. The agency is particularly interested in comments on the basic structure of the results information, including data items, pick list choices, and whether the structure is adequate to accommodate all trial designs. Preliminary versions of the results database (see below), as well as related descriptive information will be posted between May and September
2008 on this website: http://prsinfo.clinicaltrials.gov/fdaaa.html.

To access the trial database, please visit:

To submit comments based on review of the trial database, please visit:

The Federal Register notice relating to this information may be viewed
here: http://edocket.access.gpo.gov/2008/E8-11042.htm.

ISCB 2008 Accomplishments Report
January – June 2008
Download the PDF version here.

The International Society for Computational Biology is an individual membership organization that provides services and benefits to the bioinformatics and computational biology communities. In the first half of 2008 ISCB has counted 2,449 scientists and students among our membership – 55% are Professional Members, 11% are Post Docs and 34% are Students.
The following summarizes the activities and accomplishments of the ISCB through its various committees, elected leadership and staff. All initiatives of the Society are undertaken by volunteer members, and therefore ISCB gratefully acknowledges these accomplishments and thanks those named and the many more not named in this report for their selfless contributions to helping ISCB advance the science of computational biology worldwide. The initiatives of the member volunteers are supported by the ISCB staff consisting of a full time Executive Officer, two part time staff providing administrative support and database programming, two contractors on retainer to direct the conference planning logistics and serve as webmaster, and three subcontractors dedicated to the ISMB conference website, graphic design/marketing and administrative support


ISCB-ECCB Agreement for Future Joint Meetings
– The ISCB Board of Directors and Steering Committee of the European Conference on Computational Biology agreed to a long term plan to join ECCB and ISMB every other year when the Society’s ISMB meeting is held in Europe.
  • The agreement specifies shared responsibility for the scientific and logistical organization, and defines the financial responsibilities and profit sharing plan.
  • In the case of conference profits, the agreement ensures that each organization will receive an appropriate portion of the proceeds to sustain their own financial stability.
  • Thanks to ISCB President Burkhard Rost and ECCB Steering Committee Chair Michal Linial for their commitment to strengthening the relationship between the organizations in the spirit of amplifying the success of the joint meetings.
ISMB/ECCB 2007 Chairs Named – Motion presented by Executive Committee and approved by the Board of Directors to appoint the following as conference chairs for next year:
  • Gunnar von Heijne of the University of Stockholm, Sweden, to serve as Honorary Chair
  • Gene Myers of HHMI Janelia Farm Campus, USA, to serve as Conference Co-Chair
  • Marie-France Sagot of INRIA Grenoble-Rhône Alps Research Centre, France, to serve as Conference Co-Chair
ISMB Organizational Structure – Document created detailing the structure and organization of the annual ISMB conference and joint ISMB/ECCB when held together.
  • ISMB 2008 Conference Chair and ISCB President Burkhard Rost wrote first draft based on the major expansion of the conference first introduced at the 2007 joint ISMB/ECCB.
  • Members of ISMB 2008 steering committee, including ECCB steering committee chair Michal Linial, provided input and feedback toward final document.
  • Document now serves to provide current and future organizers of ISMB and ISMB/ECCB with a roadmap, and will be updated annually with the previous version retained for institutional memory.
ISCB Software Sharing Statement – The Board of Directors approved a new Software Sharing Statement for public release to replace the statement previously released in May 2002.
  • The Public Affairs & Policies Committee gathered input during a year long process of discussion within the committee, with external proponents of open source, and through a community blog to determine recommended access guidelines and draft the new statement for board approval.
  • Thanks to past committee chair Barbara Bryant along with the members of the committee and all other contributors for the tireless and sometimes trying efforts to draft a statement that encompasses the ISCB spirit of sharing software for the benefit of computation biology.
Commitment to Start an ISCB  Reserves Fund – Motion presented by Treasurer David Rocke and approved by the Board of Directors to set aside 20,000 USD annually in a reserves fund.
  • Best practices in association management suggest a minimum of six months to a year of basic operating costs be held in reserve to provide a cushion in the event of lower than necessary income
  • ISCB has never had a specific reserves fund and therefore the board felt it prudent to establish such a fund and gradually grow it to the recommended level.
C-SHALS Meeting – The Conference on Semantics in Healthcare and Life Sciences in Cambridge, MA, USA, was held in March 2008 as the first new meeting of the Society in over five years.
  • Two-day conference was attended by 67 scientists
  • Four keynotes and 14 invited speakers made up the oral presentations which were augmented by planned discussion sessions.
  • Half-day tutorial organized by the World Wide Web Consortium (W3C) preceded the conference with 25 attendees.
  • The conference was financially successful thanks to sponsorships by Pfizer, Merck & Co. and IO Informatics, and discussions are beginning on the possibility of C-SHALS 2009.
  • Thank you to Eric Neumann, Sanjoy Ray and Ted Slater who developed the concept for the conference and served as Conference Co-chairs.
Annual ISCB Awards – Selected by the Awards Committee and approved by the Executive Committee; both award winners will deliver keynote talks at ISMB 2008 in Toronto in July.
  • David Haussler of University of California Santa Cruz has been named as the ISCB 2008 Accomplishment by a Senior Scientist Award winner.
  • Aviv Regev of the Broad Institute of MIT and Harvard was named as the ISCB 2008 Overton Prize winner.
  • Thank you to Søren Brunak, Awards Committee Chair, and the members of the committee for the diligence in reviewing the nominations received and selecting the ultimate winners of the ISCB’s most prestigious awards of recognition.

The committees of ISCB are made up of members volunteering their time and expertise to a particular area of interest or an important function of the Society and the membership-at-large. The following summarizes the accomplishments of ISCB committees during the first half of 2008.
Affiliates & SIGs Committee - Tan Tin Wee, Chair
  • The Finnish Society for Bioinformatics was approved by the committee as a new ISCB Affiliated Regional Group.
Awards Committee - Søren Brunak, Chair
  • Aviv Regev (Broad Institute) was selected for the ISCB 2008 Overton Prize.
  • David Haussler (University of California, Santa Cruz) was selected for the ISCB 2008 Accomplishment by a Sr. Scientist Award.
Conferences Committee - Janet Kelso, Chair
  • Proceeds from ISMB/ECCB 2007 contributed 20,000 USD in seed funds to ECCB 2008 and 166,000 USD in seed funds to ISMB 2008.
  • Proceeds from Rocky ’07 and C-SHALS 2008 contributed a combined 30,650 USD to ISCB to help fund the operation of the Society and provide seed funds for future conferences.
  • Stockholm was approved as the site of ISMB/ECCB 2009.
  • Boston was approved as the site of ISMB 2010.
  • Three officially affiliated conferences to ISCB were held as follows:
    • PSB, January 2008, Hawaii, USA
    • AMIA Conference on Translational Medicine, March 2008, San Francisco, USA
    • RECOMB, March 2008, Singapore
Education Committee – Bruno Gaeta, Chair; Fran Lewitter, Co-chair
  • After two years in the position, Kevin Karplus stepped down as Chair of this committee in June 2008, enabling his vice chair to rise to the position of committee chair.
  • Renewed the MentorNet E-Mentoring Network Membership for a 3rd Year
Finance Committee – Jean-Francois Tomb, Chair
  • A six month plan was drafted by Dr. Tomb outlining the steps toward establishment of an endowment fund campaign.
  • All ISCB committees were polled for funding needs as the first step in the endowment fund campaign.
Nominations Committee - Dietlind Gerloff, Chair
  • Gained board approval to adopt as the standard timeline and procedure for nominations and elections of board member, officers and student council representatives.
Public Affairs & Policies Committee – David States, Chair; John Wooley, Co-chair
  • After four years in the position Barbara Bryant stepped down as Chair of this committee and nominated committee member David States to replace her.
  • Gained approval from the Board of Directors of a new ISCB Statement on Software Sharing to replace the 2002 statement of the board.
  • ISCB renewed its membership in the Federation of American Societies for Experimental Biology (FASEB).
    • Jean-Francois Tomb attended the annual Finance Committee meeting as ISCB’s representative to this committee.
    • Scott Markel attended the annual Publications & Communications Committee meeting as ISCB’s representative to this committee.
    • BJ Morrison McKay attended the annual June FASEB Board Meetings in Bethesda, Maryland, as a member of the Executive Officers Advisory Committee (EOAC), and the monthly EOAC teleconferences.
    • John Wooley attended the monthly FASEB Board teleconferences as ISCB’s voting representative to the FASEB Board of Directors.
  • Surveyed ISCB members on the challenges and issues of securing a visa for entry into the U.S.
    • Provided our member’s feedback stories to FASEB inclusion in testimony at the U.S. House of Representatives Science Committee about scientists' problems with visas in February 2008.
    • The survey and its results were mentioned in an editorial about the negative impact of visa issues published in PLoS Computational Biology in June 2008.
Publications Committee – Scott Markel, Jill Mesirov and David Rocke, Co-Chairs
  • Negotiations with Oxford University Press to reinstate “official journal” status to Bioinformatics journal have led to the ISCB Board of Directors approval of the financial arrangements and an expectation that a full contract will be ready for signature by July.
  • A survey has been designed for release in the 3rd Quarter to help ISCB understand the uses and preferences among our members of open access and traditional subscription model journals.
  • A task force was formed to investigate ISCB publishing its own journal(s).
  • An article detailing the new and exciting features of ISMB 2008 in Toronto was published in the ISCB pages of PLoS Computational Biology.

NEW TASK FORCES TARGETED TOWARD KEY NEED AREASThe executive committee identified eight areas of need for ISCB and several members of the board of directors have agreed to lead task forces to establish strategies and action plans for addressing them. Terry Gaasterland and BJ Morrison McKay will be working with the leaders to help refine and implement those strategies and action plans.Task Force Areas and Leaders:
  • Increasing ISCB membership - Nir Ben-Tal and Hannah Xue
  • Defining an ISCB Fellows program fellowship - Patricia Babbitt and Mona Singh
  • Fundraising with emphasis on corporate support - Scott Markel and Harel Weinstein
  • Financial strategies and building a reserve fund - Harel Weinstein and Patricia Babbitt
  • Filling the web portal with useful information - Olga Troyanskaya and Nir Ben-Tal
  • Recruiting affiliates - Fran Lewitter and Bruno Gaeta
  • Solidifying a role for ISMB Special Interest Groups in ISCB - Mona Singh and Fran Lewitter
  • Developing stronger Asian ties and an ISCB-North Asia meeting - Hannah Xue and Bruno Gaeta
MEMBER BENEFITS OFFERED IN THE FIRST HALF OF 2008Each year ISCB leaders and staff work on behalf of all members to ensure an array of relevant and tangible benefits are offered. In addition to the discounted journal subscription benefits that have been in place for several years, the following additional benefits were also offered during the first half of 2008:Conference Registration Discounts Secured Exclusively for ISCB Members
  • 75 USD discount to attend PSB-Pacific Symposium on Biocomputing, The Big Island of Hawaii, USA, January 2008
  • 100 SGD discount to attend RECOMB-Conference on Research in Computational Molecular Biology, Singapore, March 2008
  • 10% discount to attend Cambridge Healthtech Institute conferences:
    • BioIT World Conference & Exhibition, Boston, MA, USA, April 2008
    • Beyond Genome Conference, San Francisco, CA, USA, June 2008
Travel Fellowships from ISCB Funds Awarded to ISCB Student and Post Doc Members
  • PSB-Pacific Symposium on Biocomputing, The Big Island of Hawaii, USA, January 2008
    • 5,000 USD distributed among five paper and/or poster presenters
  • RECOMB-Conference on Research in Computational Molecular Biology, Singapore, March 2008
  • 5,000 USD distributed among ten paper and/or poster presenters

ISCB leaders and staff members participate at varying levels in several affiliated and co-sponsored bioinformatics-related conferences throughout the year in order to show support of these conferences and promote ISCB membership to prospective attendees. Additionally, e-mailings throughout the year provide news and information to ISCB members and prospects about these conferences and other matters of interest to our community. Below is a list of conferences where ISCB had a specific presence, as well as our direct mail/email marketing activities during the first half of 2008.

ISCB presentations and conference exhibition presence
  • PSB-Pacific Symposium on Biocomputing, The Big Island of Hawaii, USA, January 2008
    • Larry Hunter, ISCB Founder, held an open members meeting where he reported on the leadership structure, 2007 activities and preliminary year-end financial status of ISCB and made a promotional presentation on ISMB 2008.
    • BJ Morrison McKay, ISCB Executive Officer, represented the Society with an ISCB display in the poster hall, and presence during the conference at the PSB registration and information desk.
    • Society brochures and information were inserted in the delegate bags.

RECOMB-Conference on Research in Computational Molecular Biology, Singapore, March 2008

  • Terry Gaasterland, ISCB Vice President, made an presentation during the open business meeting where she reported on the leadership structure, 2007/2008 activities including upcoming conferences, and financial status of ISCB
  • BJ Morrison McKay represented the Society with a booth in the exhibition area.
  • ISCB brochure and ISMB 2008 poster were inserted in the delegate bags.

CHI’s BioIT World Conference & Exhibition, Boston, MA, USA, April 2008

  • BJ Morrison McKay represented the Society with a booth in the exhibition area.
  • ISCB brochure and ISMB 2008 poster were included on the literature table.

CHI’s Beyond Genome Conference, San Francisco, CA, USA, June 2008

  • BJ Morrison McKay represented the Society with a booth in the exhibition area.
  • ISCB brochure and ISMB 2008 poster were included on the literature table.
Mailings to Members and Colleagues
  • ISMB 2008 poster mailed to over 5,000 members of the bioinformatics and computational biology community
  • 14 separate ISCB announcements and conference updates distributed to over 12,000 scientists  on ISCB mailing lists via email campaign.

ISCB is governed by the leadership of 27 Board Members, including five Officers elected by the membership and who serve on the Executive Committee.  The Board and Executive Committee activities during the first half the 2008 were as follows.

Board of Directors
  • Several Board Members terms expired on January 21, 2008:
    • Barbara Bryant, Millennium Pharmaceuticals, USA
    • Michael Gribskov, Purdue University, USA
    • Vijaya Parthiban, Student Council Representative to the Board, Germany
    • Terry Speed, University of California-Berkeley, USA and Walter & Eliza Hall Institute of Medical Research, Australia
    • Lisa Vawter, Aventis, USA
  • Newly elected members of the Board took office on January 21, 2008
    • Nir Ben-Tal, Tel Aviv University, Israel
    • Fran Lewitter, Whitehead Institute, USA
    • Mona Singh, Princeton University, USA
    • John Wooley, University of California-San Diego, USA
    • Hannah Xue, Hong Kong University of Science & Technology, Hong Kong
  • Additional Board Members serving continuing terms throughout 2007 were:
    • Patricia Babbit, University of California, San Francisco, USA
    • Rita Casadio, University of Bologna, Italy
    • Manuel Corpas, Student Council Representative to the Board, EBI, UK
    • Sandro de Souza, Ludwig Center for Cancer Research, Brazil
    • Terry Gaasterland, University of California-San Diego, USA
    • Bruno Gaeta, University of New South Wales, New Zealand
    • Dietlind Gerloff, University of California-Santa Cruz, USA
    • Kevin Karplus, University of California-Santa Cruz, USA
    • Janet Kelso, Max Planck Institute for Evolutionary Anthropology, Germany
    • Thomas Lengauer, Max Planck Institute for Informatics, Germany
    • Michal Linial, The Hebrew University of Jerusalem, Israel
    • Scott Markel, Accelrys, USA
    • Jill Mesirov, The Broad Institute of Harvard and MIT, USA
    • David Rocke, University of California-Davis, USA
    • Burkhard Rost, Columbia University, USA
    • Reinhard Schneider, European Molecular Biology Laboratory, Germany
    • Tan Tin Wee, National University of Singapore, Singapore
    • Jean-Francois Tomb, DuPont, USA
    • Anna Tramontano, University of Rome, Italy
    • Olga Troyanskaya, Princeton University, USA
    • Alfonso Valencia, Spanish National Cancer Research Center, Spain
    • Harel Weinstein, Cornell University, USA
  • The Board met three times between January and June 2008 by teleconference.
Executive Committee
  • The Executive Committee members for 2008 are:
    • Burkhard Rost, President
    • Terry Gaasterland, Vice President
    • Reinhard Schneider, Vice President
    • David Rocke, Treasurer
    • Janet Kelso, Secretary
    • BJ Morrison McKay, Executive Officer (non-voting staff appointment)
  • The Executive Committee met 22 times between January and June 2008 by teleconference
    • 11 formal meetings that included key ISCB staff were conducted by teleconference.
    • 11 informal meetings of the elected officers only were conducted by teleconference.


Exclusively for members

  • Member Discount

    ISCB Members enjoy discounts on conference registration (up to $150), journal subscriptions, book (25% off), and job center postings (free).

  • Why Belong

    Connecting, Collaborating, Training, the Lifeblood of Science. ISCB, the professional society for computational biology!


Supporting ISCB

Donate and Make a Difference

Giving never felt so good! Considering donating today.